Overview

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Collaborator:

Genentech, Inc.

Treatments:

Atezolizumab